""US politics"" – Google News
A CDC study suggests that 42 percent of children ages 5-11 have coronavirus antibodies from a previous infection, leading some FDA advisors to wonder if a dose for children would be enough. The use of this study has been questioned by some scientists. FDA panelists also asked if only people with high-risk conditions like obesity should get the vaccine as it is clear that they are the most susceptible to getting very sick with Covid-19.
But CDC officials said it was tough to restrict eligibility, and the FDA advisory panel backed offering the pediatric dose for the entire age group by 17-0 with one abstention.
Dr. Marks, the FDA regulator, said Friday that the data on vaccination of children under 5 that Pfizer and Moderna are currently studying was “a few more months”.
“The risk-benefit ratio is weighed even more carefully because the youngest children are least directly affected by severe Covid-19,” he said.
Dr. Snowden said the Delta variant erased any notion that children are immune to the virus. At the height of the recent surge, Arkansas Children’s Hospital was treating up to 30 children a day for Covid, including some with fully vaccinated parents. Although that number has shrunk, “it’s still not where we were before Delta,” she said.
Much of the burden of child syringe adoption is expected to fall on pediatricians and family doctors, many of whom at this point in the pandemic are burdened by staff shortages and pent-up care needs but have deep relationships with parents and children. Dr. Sterling Ransone, the president of the American Academy of Family Physicians and a physician in rural Deltaville, Virginia, said he would keep his office open later on weekdays and Saturdays to meet demand for pediatric syringes.
“We know who to prioritize – asthmatics, heart patients, overweight people,” he said.
Dr. Victor Peralta, a pediatrician in the racially diverse neighborhood of Jackson Heights, Queens, said admission may be a little slower initially for his patients, most of whom are poor enough to have Medicaid coverage. However, he predicted that the pediatric dose would prevail and ultimately help slow down the transmission of the virus. “I have no doubt this will make a difference beyond worry,” he said.